European Pharma Innovation

Novo Nordisk's shares rose 24.9% in a month after the Danish drugmaker licensed its Parkinson's cell therapy to AI partner Cellular Intelligence and closed its internal unit. The move reflects a broader European pharma shift: incumbents are offloading early-stage biology risk to AI-native partners while retaining licensing upside. FDA Fast Track designation for the program has reduced regulatory uncertainty, reinforcing bullish sector sentiment.

UK pharmaceutical giant GSK is advancing Depemokimab, an ultra-long-acting biologic therapy, toward a late 2027 market entry. The drug represents GSK's push into extended-interval treatments that reduce dosing frequency for chronic conditions.